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ABSTRACT
In the present study, we evaluated the efficacy of trabectedin (TRAB) and 
temozolomide (TEM) compared to cisplatinum (CDDP) on a patient-derived orthotopic 
xenogrraft (PDOX) of a lung-metastasis from an osteosarcoma of a patient who failed 
CDDP therapy. Osteosarcoma resected from the patient was implanted orthotopically 
in the distal femur of mice to establish PDOX models which were randomized into the 
following groups when tumor volume reached approximately 100 mm3: G1, control 
without treatment; G2, CDDP (6 mg/kg, intraperitoneal injection, weekly, for 2 weeks); 
G3, TRAB (0.15 mg/kg, intravenous injection, weekly, for 2 weeks); G4, TEM (25 
mg/kg, oral, daily, for 14 days). Tumor size and body weight were measured with 
calipers and a digital balance, respectively, twice a week. On day 14 after initiation of 
treatment, TEM and TRAB, but not CDDP, significantly inhibited tumor volume compared 
to untreated control: control (G1): 814.5±258.8 mm3; CDDP (G2): 608.6±126.9 mm3; 
TRAB (G3): 286.6±133.0 mm3; TEM (G4): 182.9±69.1 mm3. CDDP vs. control, p=0.07; 
TRAB vs. control, p=0.0004; TEM vs. control p =0.0002; TRAB vs. CDDP, p =0.0002; 
TEM vs. CDDP, p =0.00003. The results of the present study show that a PDOX model 
of an osteosarcoma lung-metastasis that recurred after adjuvant CDDP-treatment 
has identified potentially, highly-effective drugs for this recalcitrant disease, while 
accurately maintaining the CDDP resistance of the tumor in the patient, thereby 
demonstrating the potential of the osteosarcoma PDOX model for precision oncology.
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INTRODUCTION
Osteosarcoma is a mesenchymal tumor comprising 
spindle cells and osteoid formation. Osteosarcoma 
incidence is greatest in adolescence and again in the 
seventh and eighth decades. Osteosarcoma first-line 
therapy is high-dose methotrexate, cisplatinum (CDDP), 
doxorubicin, and ifosfamide. Metastatic osteosarcoma 
has a less than 20% long-term survival rate that has not 
improved for many years [1–7].
Temozolomide (TEM) has been used clinically 
against high-grade glioma [8], melanoma [9], and 
pediatric rhabdomyosarcomas [10]. TEM has been tested 
pre-clinically against osteosarcoma cells combined with a 
molecular targeting drug [11]. TEM has also been tested 
as a single-agent against 6 osteosarcoma xenograft models 
and achieved complete response in two and stable disease 
in one [12]. Methylation of the O-6-methylguanine-
DNA methyltransferase (MGMT) gene is correlated with 
sensitivity to TEM and may become as a biomarker for 
TEM. Methylation of the MGMT gene occurred in 23.5% 
of osteosarcoma patients in one study [13].
Trabectedin (TRAB) is an alkylating agent 
derived from the Caribbean tunicate, Ecteinascidia 
turbinate [14]. TRAB has been tested on patients 
with liposarcoma and leiomyosarcoma [15, 16]. 
TRAB arrests cells in the G2/M phase of the cell 
cycle [17]. TRAB has shown efficacy against CDDP-
resistant bone cancer in vitro [18]. TRAB is marketed 
as Yondelis (Johnson & Johnson, Raritan, NJ) for 
leiomyosarcoma and liposarcoma. (https://www.
cancer.gov/news-events/cancer-currents-blog/2015/
fda-trabectedin-sarcoma).
TRAB has been used for recurrent osteosarcoma 
patients with a 12% partial response rate [19]. Patients with 
metastatic osteosarcoma that had the wild-type AAP1164 
excision-repair cross-complementing 5 (ERCC5) gene had 
major responses to TRAB [20], suggesting this gene could 
be a biomarker for TRAB.
We previously reported that a subcutaneous 
transplant nude-mouse model of an ostoeosarcoma lung 
metastasis that occurred after adjuvant CDDP treatment 
of the patient, was regressed by tumor-targeting 
Salmonella typhimurium A1-R (S. typhimurium A1-R). 
The osteosarcoma was only partially sensitive to the 
molecular-targeting drug sorafenib, which did not arrest 
its growth. S. typhimurium A1-R was significantly more 
effective than sorafenib [21].
We previously developed the orthotopic intratibial-
implantation model using a human osteosarcoma cell 
line in nude mice [22]. In the intratibial orthotopic 
osteosarcoma model, we observed by color-coded 
imaging, when high- and low-metastatic osteosarcoma 
cell lines were co-transplanted, there was gene exchange 
between the cell lines in vivo resulting in the conversion 
of the low-metastatic cell line to high-metastatic [23]. In 
another previous study from our laboratory, the intratibial 
orthotopic osteosarcoma model used fluorescent-protein-
expressing human osteosarcoma cells in order to develop 
fluorescence-guided surgery (FGS) which reduced 
multiple lung metastasis and thereby increased mouse 
survival time [24]. Echistatin, a cyclic RGD peptide, 
which is an antagonist of αvβ3 integrin (disintegrin), 
inhibited primary tumor growth as well as pulmonary 
metastases in a human osteosarcoma cell line in the 
intratibial orthotopic model used in a previous study in 
our laboratory [25].
Toward the goal of individualized precision 
oncology, our laboratory pioneered the patient-derived 
orthotopic xenograft (PDOX) nude mouse model with 
the technique of surgical orthotopic implantation (SOI), 
including pancreatic [26–29], breast [30], ovarian [31], 
lung [32], cervical [33], colon [34–36], and stomach 
cancer [37], sarcoma [38–42] and melanoma [43–45].
In the present study, we tested a PDOX model 
established from an osteosarcoma lung metastasis that 
recurred after adjuvant cisplatinum treatment of the 
patient, for sensitivity to CDDP, TRAB and TEM.
RESULTS AND DISCUSSION
Efficacy of CDDP, TRAB and TEM on the 
osteosarcoma PDOX mouse model
All drugs but CDDP significantly inhibited tumor 
volume compared to untreated control on day 14 after 
treatment initiation: control (G1): 814.5±258.8 mm3; 
CDDP (G2): 608.6±126.9 mm3; TRAB (G3): 286.6±133.0 
mm3; TEM (G4): 182.9±69.1 mm3. CDDP vs. control, 
p=0.07; TRAB vs. control, p=0.0004; TEM vs. control, 
p =0.0002; TRAB vs. CDDP, p =0.0002; TEM vs. CDDP, 
p =0.00003; TEM vs. TRAB, p=0.025 (Figure 1). There 
were no animal deaths in any group. Body weight of the 
treated mice was not significantly different from untreated 
control in any group (Figure 2).
Histology of original patient tumor and control 
and treated tumors
Hematoxylin and eosin (H&E)-stained sections 
were made from the patient and mouse-grown tumors. 
The original patient osteosarcoma tumor had hypercellular 
areas populated by anaplastic cells displaying nuclear 
pleomorphism, coarse and hyperchromatic chromatin 
and abundant mitotic figures (Figure 3A). The 
subcutaneously-implanted mouse-grown tumor contained 
hypercellular areas with anaplastic cells displaying nuclear 
pleomorphism, coarse and hyperchromatic chromatin and 
mitotic figures. A chondroid matrix was less abundant 
compared to the original patient tumor (Figure 3B). The 
low magnification image of the untreated PDOX tumor 
shows cortical and medullary infiltration of tumor as 
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Figure 1: Efficacy of cisplatinum (CDDP), trabectedin (TRAB) and temozolomide (TEM) on the osteosarcoma PDOX. 
Osteosarcoma tissue was grown orthotopically in the right distal femur of nude mice and allowed to form tumors. (A) Mice were treated 
with CDDP (6 mg/kg, i.p., qw×2); TRAB (0.15 mg/kg, i.v., qw×2); and TEM (25 mg/kg, p.o., qd×14). Tumor volume was measured at the 
indicated time points after the onset of treatment. n=8 mice/group. (B) Tumor growth curves of treated and untreated mice. (C) Photos of 
representative treated and untreated osteosarcoma PDOX models. * p< 0.05, **p< 0.001
Figure 2: Body weights after CDDP, TRAB and TEM treatment. Bar graph shows body weight in each group at pre-treatment 
and 2 weeks after drug administration.
Oncotarget62114www.impactjournals.com/oncotarget
Figure 3: Osteosarcoma histology. H&E-stained sections of (A) the original patient tumor (micro). (B) Subcutaneously-implanted 
tumor (micro). (C) Orthotopically-implanted tumor (macro). (D) Orthotopically-implanted tumor (micro). (E) PDOX tumor treated with 
CDDP. (F) PDOX tumor treated with TRAB. (G) PDOX tumor treated with TEM. Necrotic areas are indicated by yellow arrows. Scale 
bars: 100 μm for (A, B, D). Black scale bar: 2 mm for C. Scale bars: 80 μm for (E-G).
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well as muscle infiltration (Figure 3C). A high power 
photomicrograph of the untreated PDOX tumor shows a 
chondroblastic appearance similar to the patient’s original 
tumor with hypercellular areas filled with tumor cells 
displaying nuclear pleomorphism and mitotic figures 
(Figure 3D). PDOX tumors treated with CDDP were 
comprised of viable cells without apparent necrosis or 
inflammatory changes and almost the same features 
compared to the untreated control (Figure 3E). Tumors 
treated with TRAB showed changes in cancer-cell shape 
with slight necrosis (Figure 3F). TEM-treated tumors 
showed more extensive tumor necrosis (Figure 3G), which 
is consistent with the superior efficacy of TEM.
Recurrent metastatic osteosarcoma that has failed 
first-line therapy is a recalcitrant cancer. The results of 
the present study suggest that novel active drugs can be 
identified for this disease using the PDOX model. Further 
studies are necessary to determine the clinical significant of 
the present findings. The PDOX model of lung metastatic 
osteosarcoma that failed CDDP treatment replicated the 
clinical outcome of CDDP treatment of the patient.
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [46–51].
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., 
San Diego, CA), 4–6 weeks old, were used in this 
study. Animals were housed in a barrier facility on a 
high efficiency particulate arrestance (HEPA)-filtered 
rack under standard conditions of 12-hour light/dark 
cycles. The animals were fed an autoclaved laboratory 
rodent diet. All animal studies were conducted with 
an AntiCancer Institutional Animal Care and Use 
Committee (IACUC)-protocol specifically approved 
for this study and in accordance with the principles and 
procedures outlined in the National Institute of Health 
Guide for the Care and Use of Animals under Assurance 
Number A3873-1. In order to minimize any suffering 
of the animals, anesthesia and analgesics were used for 
all surgical experiments. Animals were anesthetized 
by subcutaneous injection of a 0.02 ml solution of 20 
mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate. The response of animals during 
surgery was monitored to ensure adequate depth of 
anesthesia. The animals were observed on a daily basis 
and humanely sacrificed by CO2 inhalation when they 
met the following humane endpoint criteria: severe tumor 
Figure 4: Establishment of the osteosarcoma PDOX model. (A) A skin incision was made on the right thigh. (B) The vastas 
lateralis muscle and biceps femoris muscle were split to reach the distal femur. (C) The lateral condyle of the distal femur was resected. (D) 
A single 3 mm tumor fragment was implanted orthotopically into the space. (E) The muscle was closed with a 6-0 nylon suture. (F) The 
tumor fragment was totally covered by the muscle.
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burden (more than 20 mm in diameter), prostration, 
significant body weight loss, difficulty breathing, 
rotational motion and body temperature drop.
Patient-derived tumor
The study was previously reviewed and approved 
by the UCLA Institutional Review Board (IRB #10-
001857) [17]. Written informed consent was obtained 
from the patient as part of the above-mentioned UCLA 
Institutional Review Board-approved protocol. A 16-
year old patient with localized left-distal-femoral 
high-grade osteosarcoma underwent CDDP-based neo-
adjuvant chemotherapy and limb salvage with distal 
femoral replacement. One year later, the osteosarcoma 
recurred with three bilateral metachronous pulmonary 
metastases. The patient was treated with curative 
surgery at the Division of Surgical Oncology, University 
of California, Los Angeles (UCLA). The patient did 
not receive chemotherapy or radiotherapy after tumor 
occurrence prior to lung surgery [21].
Surgical orthotopic implantation (SOI) for 
establishment of the PDOX osteosarcoma model
A lung metastasis from the osteosarcoma patient 
was previously established subcutaneously in mice [21]. 
Subcutaneously grown tumors were harvested and cut 
into small fragments (3-4 mm). After nude mice were 
anesthetized, a 10 mm skin incision was made on the 
right thigh, the vastus lateralis muscle was opened and 
the biceps femoris muscle was split to reach the distal 
femur. An incision was made in the lateral patello-femoral 
ligament, sparing the knee joint and then the lateral 
condyle of the femur was resected. A single 3 to 4 mm 
tumor fragment was implanted orthotopically into the 
space to establish a PDOX model. The muscle and wound 
was closed with 6-0 nylon suture (Ethilon, Ethicon, Inc., 
NJ, USA) (Figure 4).
Treatment design
The PDOX models were randomized into the 
following groups when tumor volumes reached 100 
mm3: G1, control without treatment, n=8; G2, CDDP 
(6 mg/kg, intraperitoneal [i.p.] qw×2, n=8); G3, TRAB 
(0.15 mg/kg, intravenous [i.v.], qw×2, n=8); G4, TEM 
(25 mg/kg, per oral [p.o.], qd×14, n=8). The schedule 
for TRAB and TEM, as well as CDDP, were obtained 
from previously published results [43–45, 52]. Tumor 
length, width and mouse body weight were measured 
twice in a week. Tumor volume was calculated by 
following formula: Tumor volume (mm3) = length (mm) 
× width (mm) × width (mm) × 1/2. Data are presented 
as mean ± SD.
Histological analysis
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (3 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocol. Histological examination was performed with 
a BHS system microscope. Images were acquired with 
INFINITY ANALYZE software (Lumenera Corporation, 
Ottawa, Canada).
CONCLUSIONS
In the present study, the PDOX model identified 
TEM and TRAB as potential effective drugs for a recurrent, 
recalcitrant, CDDP-resistant metastatic  osteosarcoma. The 
PDOX model precisely replicated the CDDP resistance 
of the patients recurring lung metastasis, suggesting the 
patient will have a possibility to respond to TEM or TRAB, 
which were effective in the PDOX model. Our results are 
of particular importance for TRAB, which is marketed as 
Yondelis for leiomyosarcoma and liposarcoma, since the 
results demonstrate activity of this drug in CDDP-resistant 
metastatic osteosarcoma. However, further studies are 
needed to determine the clinical potential of TRAB for this 
disease. In particular, more effective schedules of TRAB, 
as well as combination drugs need to be identified in the 
PDOX models at doses that can also be achieved clinically.
Future experiments will include mechanistic 
experiments on the differential activity of TRAB and 
TEM compared to CDDP as well as identifying molecular-
signaling pathways that are activated by these compounds, 
especially in PDOX models of patients that express 
biomarkers for these drugs.
Our results show the potential of the PDOX model 
for refractory, recurrent osteosarcoma model for precision 
oncology.
Both TRAB and TEM showed strong inhibition 
(Figure 1B, 1C) almost arresting tumor growth and 
causing extensive tumor necrosis (Figure 3F, 3G). This 
very promising result will be used in future experiments 
to design combination drug experiments in order to obtain 
tumor regression in PDOX models and thereby be of 
potential use for clinical efficacy.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This study was supported in part by the National 
Cancer Institute grant CA213649.
Oncotarget62117www.impactjournals.com/oncotarget
REFERENCES
1. Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi 
A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma 
of the limb: amputation or limb salvage in patients treated 
by neoadjuvant chemotherapy. J Bone Joint Surg Br. 
2002;84:88-92.
2. Muscolo DL, Ayerza MA, Aponte-Tinao LA, Ranalletta 
M. Partial epiphyseal preservation and intercalary allograft 
reconstruction in high-grade metaphyseal osteosarcoma of 
the knee. J Bone Joint Surg Am. 2004;86:2686-2693.
3. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb 
salvage treatment versus amputation for osteosarcoma 
of the distal end of the femur. J Bone Joint Surg Am. 
1986;68:1331-1337.
4. Lewis VO. What’s new in musculoskeletal oncology. J 
Bone Joint Surg Am. 2007;89:1399-1407.
5. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, 
Huvos AG, Healey JH. Intensification of preoperative 
chemotherapy for osteogenic sarcoma: results of the 
Memorial Sloan-Kettering (T-12) protocol. J Clin Oncol. 
1998;16:2452-2458.
6. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, 
Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-
Kuntschik M, Weinel P, Werner M, et al. Long-term results 
of the cooperative German-Austrian-Swiss osteosarcoma 
study group’s protocol COSS-86 of intensive multidrug 
chemotherapy and surgery for osteosarcoma of the limbs. 
Ann Oncol. 1998;9:893-899.
7. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, 
Capanna R, Donati D, Lari S, Forni C, DePaolis M. 
Neoadjuvant chemotherapy for osteosarcoma of the 
extremity: long-term results of the Rizzoli’s 4th protocol. 
Eur J Cancer. 2001;37:2030-2039.
8. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, 
Brada M, Friedman HS, Albright R, Olson J, Chang 
SM, O’Neill AM, Friedman AH, Bruner J, Yue N, et al. 
Multicenter phase II trial of temozolomide in patients with 
anaplastic astrocytoma or anaplastic oligoastrocytoma at 
first relapse. Temodal Brain Tumor Group. J Clin Oncol. 
1999;17:2762-2771.
9. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, 
Calvert AH, Rustin GJ, Brampton M, Stevens MF. Cancer 
Research Campaign phase II trial of temozolomide in 
metastatic melanoma. J Clin Oncol. 1995;13:910-913.
10. Winter S, Fasola S, Brisse H, Mosseri V, Orbach D. 
Relapse after localized rhabdomyosarcoma: evaluation of 
the efficacy of second-line chemotherapy. Pediatr Blood 
Cancer. 2015;62:1935-1941.
11. Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. 
Osteosarcoma cells with genetic signatures of BRCAness 
are susceptible to the PARP inhibitor talazoparib alone or 
in combination with chemotherapeutics. Oncotarget. 2017; 
8:48794-48806. doi: 10.18632/oncotarget.10720.
12. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, 
Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva 
RT, Houghton PJ, Smith MA. Initial testing (stage 1) of 
temozolomide by the pediatric preclinical testing program. 
Pediatr Blood Cancer. 2013;60:783-790.
13. Cui Q, Jiang W, Guo J, Liu C, Li D, Wang X, Zeng Y. 
Relationship between hypermethylated MGMT gene and 
osteosarcoma necrosis rate after chemotherapy. Pathol 
Oncol Res. 2011;17:587-591.
14. Cuevas C, Francesch A. Development of Yondelis 
(trabectedin, ET-743). A semisynthetic process solves the 
supply problem. Nat Prod Rep. 2009;26:322-337.
15. Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel 
N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios 
M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci 
F, et al. Trabectedin in patients with advanced soft tissue 
sarcoma: a retrospective national analysis of the French 
Sarcoma Group. Eur J Cancer. 2015;51:742-750.
16. Demetri GD, von Mehren M, Jones RL, Hensley ML, 
Schuetze S, Staddon AP, Milhem MM, Elias AD, Ganjoo 
KN, Tawbi HA, Van Tine BA, Spira AI, Dean AP, et 
al. A randomized phase III study of trabectedin (T) or 
dacarbazine (D) for the treatment of patients (pts) with 
advanced liposarcoma (LPS) or leiomyosarcoma (LMS) 
[abstract]. J Clin Oncol. 2015;33:A10503.
17. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce 
S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini 
F, Nebuloni M, van Rooijen N, Mortarini R, et al. Role 
of macrophage targeting in the antitumor activity of 
trabectedin. Cancer Cell. 2013;23:249-262.
18. Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, 
Cerisano V, Strammiello R, Mercuri M, Reverter-Branchat 
G, Faircloth G, D’Incalci M, Picci P. Effectiveness of 
Ecteinascidin-743 against drug-sensitive and -resistant bone 
tumor cells. Clin Cancer Res. 2002;8:3893-3903.
19. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers 
PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos 
AG, Goorin AM, Bagatell R, Ruiz-Casado A, et al. Phase 
II study of ecteinascidin 743 in heavily pretreated patients 
with recurrent osteosarcoma. Cancer. 2003;98:832-840.
20. Gastaud L, Saâda-Bouzid E, Le Morvan V, Pourquier P, 
Ianessi A, Thariat J, Italiano A, Thyss A. Major efficacy 
of trabectedin in 2 metastatic osteosarcoma patients with 
wild-type Asp1104 ERCC5 tumor status. Onkologie. 
2013;36:670-673.
21. Murakami T, Igarashi K, Kawaguchi K, Kiyuna T, Zhang Y, 
Zhao M, Hiroshima Y, Nelson SD, Dry SM, Li Y, Yanagawa 
J, Russell T, Federman N, et al. Tumor-targeting Salmonella 
typhimurium A1-R regresses an osteosarcoma in a patient-
derived xenograft model resistant to a molecular-targeting 
drug. Oncotarget. 2017;8:8035-8042. doi: 10.18632/
oncotarget.14040.
22. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, 
Tomita K, Kishimoto H, Bouvet M, Hoffman RM. Systemic 
Oncotarget62118www.impactjournals.com/oncotarget
targeting of primary bone tumor and lung metastasis of high-
grade osteosarcoma in nude mice with a tumor-selective strain 
of Salmonella typhimurium. Cell Cycle. 2009;8:870-875.
23. Tome Y, Tsuchiya H, Hayashi K, Yamauchi K, Sugimoto 
N, Kanaya F, Tomita K, Hoffman RM. in vivo gene transfer 
between interacting human osteosarcoma cell lines is 
associated with acquisition of enhanced metastatic potential. 
J Cell Biochem. 2009;108:362-367.
24. Miwa S, Hiroshima Y, Yano S, Zhang Y, Matsumoto Y, 
Uehara F, Yamamoto M, Kimura H, Hayashi K, Bouvet M, 
Tsuchiya H, Hoffman RM. Fluorescence-guided surgery 
improves outcome in an orthotopic osteosarcoma nude-
mouse model. J Orthop Res. 2014;32:1596-1601.
25. Tome Y, Kimura H, Sugimoto N, Tsuchiya H, Kanaya F, 
Bouvet M, Hoffman RM. The disintegrin echistatin, in 
combination with doxorubicin targets high-metastastic 
human osteosarcoma overexpressing α
ν
β
3
 integrin in 
chick embryo and nude mouse models. Oncotarget. 
2016;7:87031-87036. doi: 10.18632/oncotarget.13497.
26. Hiroshima Y, Zhang Y, Murakami T, Maawy A, Miwa 
S, Yamamoto M, Yano S, Sato S, Momiyama M, Mori 
R, Matsuyama R, Chishima T, Tanaka K, et al. Efficacy 
of tumor-targeting Salmonella typhimurium A1-R in 
combination with anti-angiogenesis therapy on a pancreatic 
cancer patient-derived orthotopic xenograph (PDOX) and 
cell line mouse models. Oncotarget. 2014;5:12346-12357. 
doi: 10.18632/oncotarget.2641.
27. Fu X, Guadagni F, Hoffman RM. A metastatic nude-
mouse model of human pancreatic cancer constructed 
orthotopically with histologically intact patient specimens. 
Proc Natl Acad Sci U S A. 1992;89:5645-5649.
28. Hiroshima Y, Maawy A, Zhang Y, Murakami T, Momiyama 
M, Mori R, Matsuyama R, Katz MH, Fleming JB, Chishima 
T, Tanaka K, Ichikawa Y, Endo I, et al. Metastatic recurrence 
in a pancreatic cancer patient derived orthotopic xenograft 
(PDOX) nude mouse model is inhibited by neoadjuvant 
chemotherapy in combination with fluorescence-guided 
surgery with an anti-CA 19–9-conjugated fluorophore. 
PLoS One. 2014;9:e114310.
29. Hiroshima Y, Maawy AA, Katz MH, Fleming JB, Bouvet 
M, Endo I, Hoffman RM. Selective efficacy of zoledronic 
acid on metastasis in a patient-derived orthotopic xenograph 
(PDOX) nude-mouse model of human pancreatic cancer. J 
Surg Oncol. 2015;111:311-315.
30. Fu X, Le P, Hoffma RM. A metastatic-orthotopic transplant 
nude-mouse model of human patient breast cancer. 
Anticancer Res. 1993;13:901-904.
31. Fu X, Hoffman RM. Human ovarian carcinoma 
metastatic models constructed in nude mice by orthotopic 
transplantation of histologically-intact patient specimens. 
Anticancer Res. 1993;13:283-286.
32. Wang X, Fu X, Hoffman RM. A new patient-like metastatic 
model of human lung cancer constructed orthotopically 
with intact tissue via thoracotomy in immunodeficient mice. 
Int J Cancer. 1992;51:992-995.
33. Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, 
Yamamoto M, Uehara F, Miwa S, Yano S, Murakami T, 
Momiyama M, Chishima T, Tanaka K, et al. Establishment 
of a patient-derived orthotopic xenograph (PDOX) model 
of HER-2-positive cervical cancer expressing the clinical 
metastatic pattern. PLoS One. 2015;10:e0117417.
34. Fu X, Besterman JM, Monosov A, Hoffman, RM. Models of 
human metastatic colon cancer in nude mice orthotopically 
constructed by using histologically intact patient specimens. 
Proc Natl Acad Sci U S A. 1991;88:9345-9349.
35. Metildi CA, Kaushal S, Luiken GA, Talamini MA, Hoffman 
RM, Bouvet M. Fluorescently-labeled chimeric anti-CEA 
antibody improves detection and resection of human colon 
cancer in a patient-derived orthotopic xenograft (PDOX) 
nude mouse model. J Surg Oncol. 2014;109:451-458.
36. Hiroshima Y, Maawy A, Metildi CA, Zhang Y, Uehara 
F, Miwa S, Yano S, Sato S, Murakami T, Momiyama 
M, Chishima T, Tanaka K, Bouvet M, et al. Successful 
fluorescence-guided surgery on human colon cancer 
patient-derived orthotopic xenograft mouse models 
using a fluorophore-conjugated anti-CEA antibody and a 
portable imaging system. J Laparoendosc Adv Surg Tech 
A. 2014;24:241-247.
37. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman 
RM. Orthotopic transplantation of histologically intact 
clinical specimens of stomach cancer to nude mice: 
correlation of metastatic sites in mouse and individual 
patient donors. Int J Cancer. 1993;53:608-612.
38. Murakami T, DeLong J, Eilber FC, Zhao M, Zhang Y, 
Zhang N, Singh A, Russell T, Deng S, Reynoso J, Quan 
C, Hiroshima Y, Matsuyama R, et al. Tumor-targeting 
Salmonella typhimurium A1-R in combination with 
doxorubicin eradicate soft tissue sarcoma in a patient-
derived orthotopic xenograft PDOX model. Oncotarget. 
2016;7:12783-12790. doi: 10.18632/oncotarget.7226.
39. Hiroshima Y, Zhao M, Zhang Y, Zhang N, Maawy A, 
Murakami T, Mii S, Uehara F, Yamamoto M, Miwa S, 
Yano S, Momiyama M, Mori R, et al. Tumor-targeting 
Salmonella typhimurium A1-R arrests a chemo-resistant 
patient soft-tissue sarcoma in nude mice. PLoS One. 
2015;10:e0134324.
40. Kiyuna T, Murakami T, Tome Y, Kawaguchi K, Igarashi K, 
Zhang Y, Zhao M, Li Y, Bouvet M, Kanaya F, Singh A, 
Dry S, Eilber FC, et al. High efficacy of tumor-targeting 
Salmonella typhimurium A1-R on a doxorubicin- and 
dactolisib-resistant follicular dendritic-cell sarcoma in a 
patient-derived orthotopic xenograft PDOX nude mouse 
model. Oncotarget. 2016;7:33046-33054. doi: 10.18632/
oncotarget.8848.
41. Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James 
AW, Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, 
Hiroshima Y, Russell T, Eckardt MA, et al. Effective 
molecular targeting of CDK4/6 and IGF-1R in a rare FUS-
ERG fusion CDKN2A-deletion doxorubicin-resistant 
Ewing’s sarcoma in a patient-derived orthotopic xenograft 
Oncotarget62119www.impactjournals.com/oncotarget
(PDOX) nude-mouse model. Oncotarget. 2016;7:47556-
47564. doi: 10.18632/oncotarget.9879.
42. Hiroshima Y, Zhang Y, Zhang N, Uehara F, Maawy A, 
Murakami T, Mii S, Yamamoto M, Miwa S, Yano S, 
Momiyama M, Mori R, Matsuyama R, et al. Patient-derived 
orthotopic xenograft (PDOX) nude mouse model of soft-
tissue sarcoma more closely mimics the patient behavior in 
contrast to the subcutaneous ectopic model. Anticancer Res. 
2015;35:697-701.
43. Yamamoto M, Zhao M, Hiroshima Y, Zhang Y, Shurell E, 
Eilber F,C, Bouvet M, Noda M, Hoffman RM. Efficacy 
of tumor-targeting Salmonella typhimurium A1-R on a 
melanoma patient-derived orthotopic xenograft (PDOX) 
nude-mouse model. PLoS One. 2016;11:e0160882.
44. Kawaguchi K, Murakami T, Chmielowski B, Igarashi K, 
Kiyuna T, Unno M, Nelson SD, Russell TA, Dry SM, Li 
Y, Eilber FC, Hoffman RM. Vemurafenib-resistant BRAF-
V600E mutated melanoma is regressed by MEK targeting 
drug trametinib, but not cobimetinib in a patient-derived 
orthotopic xenograft (PDOX) mouse model. Oncotarget. 
2016;7:71737-71743. doi: 10.18632/oncotarget.12328.
45. Kawaguchi K, Igarashi K, Murakami T, Chmiewloski B, 
Kiyuna T, Zhao M, Zhang Y, Singh A, Unno M, Nelson SD, 
Russell T, Dry SM, Li Y, et al. Tumor-targeting Salmonella 
typhimurium A1-R combined with Temozolomide 
regresses malignant melanoma with a BRAF-V600 
mutation in a patient-derived orthotopic xenograft (PDOX) 
model. Oncotarget. 2016;7:85929-85936. doi: 10.18632/
oncotarget.13231.
46. Blagosklonny MV. Matching targets for selective cancer 
therapy. Drug Discov Today. 2003;8:1104-1107.
47. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell 
Cycle. 2005;4:1518-1521.
48. Blagosklonny MV. Treatment with inhibitors of caspases, 
that are substrates of drug transporters, selectively 
permits chemotherapy-induced apoptosis in multidrug-
resistant cells but protects normal cells. Leukemia. 
2001;15:936-941.
49. Blagosklonny MV. Target for cancer therapy: proliferating 
cells or stem cells. Leukemia. 2006;20:385-391.
50. Apontes P, Leontieva OV, Demidenko ZN, Li F, 
Blagosklonny MV. Exploring long-term protection 
of normal human fibroblasts and epithelial cells from 
chemotherapy in cell culture. Oncotarget. 2011;2:222-233. 
doi: 10.18632/oncotarget.248.
51. Blagosklonny MV. Tissue-selective therapy of cancer. Br J 
Cancer. 2003;89:1147-1151.
52. Kawaguchi K, Igarashi K, Murakami T, Kiyuna T, Lwin 
T, Hwang HK, DeLong J, Clary B, Bouvet M, Unno M, 
Hoffman RM. MEK inhibitors cobimetinib and trametinib, 
regressed a gemcitabine-resistant pancreatic cancer patient-
derived orthotopic xenograft (PDOX). Oncotarget. 2017; 
8:47490-47496. doi: 10.18632/oncotarget.17667.
